ACT-AD Holds First Symposium at an Internationally-Recognized Conference
October 29, 2012
ACT-AD held its first symposium at an internationally-recognized conference. The program titled “Harmonizing Global Regulatory Standards to Benefit Future Alzheimer’s Disease Patients” takes place during the 5th Clinical Trials in Alzheimer’s Disease (CTAD) Conference. The program is comprised of presentations by regulators from the US and Europe as well as representatives involved in global efforts to standardize data, biochemical assays, and neuroimaging protocols for Alzheimer’s disease (AD). The purpose is to shed light on similarities and differences between FDA and EMA requirements for achieving disease modification in pre-symptomatic AD patients—with a goal of highlighting how, in addition to guidance, new regulatory science initiatives could expedite drug development.
On October 30, ACT-AD sponsors an informal meeting of leading Alzheimer’s experts from the U.S. and Europe to provide an opportunity for these experts to share their insights into how the development of novel AD therapies could be improved.